Escitalopram
NDC Package 67046-1356-3

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Escitalopram is tablets are contraindicated in patients:taking MAOIs with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets because of an increased risk of serotonin syndrome. Marketed by Coupler Llc, this product is identified by NDC 67046-1356 and is authorized under FDA application ANDA078032.

Identification & Billing

NDC Package Code
67046-1356-3
Package Description
30 TABLET, FILM COATED in 1 BLISTER PACK
Product Code
11-Digit Billing Format
67046135603
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Escitalopram
Dosage Form
-
Usage Information
Escitalopram tablets are contraindicated in patients:taking MAOIs with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets because of an increased risk of serotonin syndrome. The use of escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated [ see Dosage and Administration( 2.7) and Warnings and Precautions( 5.2)]. Starting escitalopram tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [ see Dosage and Administration( 2.6) and Warnings and Precautions( 5.2)]. taking pimozide [ see Drug Interactions( 7)]. with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in escitalopram tablets.

Regulatory & Marketing

Labeler Name
Coupler Llc
FDA Application #
ANDA078032
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-11-2024
Listing Expiration
12-31-2025
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 67046-1356-3 identifies a specific commercial package of 30 tablet, film coated in 1 blister pack of Escitalopram, labeled by Coupler Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Coupler Llc on November 11, 2024. The current certification is valid through December 31, 2025.

How is this Coupler Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 67046135603. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
67046-1356-3
11-Digit CMS (5-4-2)
67046-1356-03

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.